Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Single-group Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Adult Patients With Pulmonary Arterial Hypertension

NCT02471183 is registered in ClinicalTrials.gov with Actelion as lead sponsor.

NCT NCT02471183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02471183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Single-group Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Adult Patients With Pulmonary Arterial Hypertension
Lead sponsor
Actelion
Phase
Phase 3
Overall status
Completed
Start date
October 12, 2015
Completion date
December 5, 2016
Enrollment
34 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension